AstraZeneca PLC (LON:AZN)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 158.45B |
| Revenue (ttm) | 42.56B |
| Net Income (ttm) | 6.02B |
| Shares Out | 1.55B |
| EPS (ttm) | 3.85 |
| PE Ratio | 26.57 |
| Forward PE | 14.94 |
| Dividend | 2.35 (2.27%) |
| Ex-Dividend Date | Feb 20, 2025 |
| Volume | 802,661 |
| Average Volume | 1,942,878 |
| Open | 10,360 |
| Previous Close | 10,336 |
| Day's Range | 10,172 - 10,368 |
| 52-Week Range | 9,574 - 13,388 |
| Beta | 0.17 |
| RSI | 42.53 |
| Earnings Date | Jul 29, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
Top global stories this week: Banco Santander, Alibaba, AstraZeneca among notable names
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Why AstraZeneca Stock Got Thumped on Thursday
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2218899804-b82cc3c6fc7f442fb508daa6c804cff9.jpg)
Summit Therapeutics Stock Soars on Report of $15B AstraZeneca Partnership Talks
Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with AstraZeneca.
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
In a high-stakes maneuver that could reshape the oncology landscape, AstraZeneca Plc (NASDAQ: AZN) is reportedly in talks with Summit Therapeutics Inc. (NASDAQ: SMMT) about a partnership worth up to...
Report: Summit in talks for $15 billion partnership with AstraZeneca
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on AstraZeneca
Report: Summit in talks for $15 billion partnership with AstraZeneca
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on AstraZeneca
Summit considers up to $15 billion partnership with AstraZeneca, Bloomberg News reports
Summit Therapeutics is considering an up to $15 billion partnership with AstraZeneca , Bloomberg News reported on Thursday, citing people familiar with the matter.
New London IPOs hit 28-year low amid AstraZeneca exit concerns
More than $100 billion worth of London-listed companies have announced or executed plans to move to New York in recent years.
Wise Becomes the Latest UK Giant to Eye a Transatlantic Escape
Wise plans to move its primary listing from London to the US for better capital access, joining AstraZeneca and others in doing so. The post Wise Becomes the Latest UK Giant to Eye a Transatlantic Esc...
Price Over Earnings Overview: AstraZeneca
In the current session, AstraZeneca Inc. (NASDAQ: AZN) is trading at $71.17, after a 0.41% decrease. Over the past month, the stock fell by 2.51% , and in the past year, by 7.98% . With performance l...
If AstraZeneca goes to the US it will be a major blow for London and Labour
Move would deprive LSE of its biggest star and could topple a key pillar of the government’s industrial strategy Three years ago Pascal Soriot received the ultimate accolade for turning around AstraZe...
AstraZeneca exit: here's what it really means for the UK
AstraZeneca Plc (LON: AZN) is in focus this morning following reports that its chief executive – Pascal Soriot is considering moving the giant's listing to the US.
AstraZeneca Navigates Challenges and Opportunities in 2025
As of July 2, 2025, AstraZeneca, the largest company according to market capitalization of the largest country the United Kingdom, is still a key to the world scenario in the global pharmaceutical mar...
London stock market could weather its biggest blow yet if AstraZeneca exits
AstraZeneca is the most valuable company listed on Londons FTSE 100 index.
London’s New Listings Hit 28-Year Low as AstraZeneca Weighs Exit
London marked the slowest first half-year for IPO volume since 1997, a grim milestone punctuated by a report that AstraZeneca Plc’s chief executive officer wants to move the company’s listing to the U...
Astra reportedly looks to move its listing across the Atlantic
The Times reports that AstraZeneca, the U.K.'s most valuable public company, is looking to move its listing from London to the U.S. - in a move that could strip the FTSE 100 of a firm that accounts fo...
AstraZeneca exit is a frightening prospect for the City and the government
It's a threat that will send a shiver down the spine of Downing Street and shake the City of London to its core..
Why AstraZeneca Stock Topped the Market on Tuesday
AstraZeneca boss ‘wants to shift stock market listing to US’
Report claims CEO Pascal Soriot talked in private about moving UK’s most valuable listed company and considered shifting its domicile AstraZeneca’s chief executive Pascal Soriot has reportedly said th...
AstraZeneca Shares Rise as CEO Eyes US Stock Market Move
AstraZeneca’s 2.6% share jump follows CEO’s US listing hint, another major blow to London’s stock market pride. The post AstraZeneca Shares Rise as CEO Eyes US Stock Market Move appeared first on Inve...
AstraZeneca rises after report on U.S. listing plans
AstraZeneca CEO eyes US market listing, The Times reports
AstraZeneca chief executive Pascal Soriot is considering moving the company's stock market listing to the United States, The Times reported on Tuesday, citing multiple sources.
AstraZeneca: Navigating Challenges Across Geographies Well
Onco-Innovations Welcomes AstraZeneca's Interest in Founding Role in PROmAI - an Inka-led AI-Oncology Consortium
VANCOUVER, BC / ACCESS Newswire / June 27, 2025 / Onco-Innovations Limited(CBOE CA:ONCO)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly-owned subsidiary, I...